Artesunate PCD Pharma Franchise Company

Cafoli Lifecare is a WHO-GMP certified pharmaceutical company offering a Artesunate PCD pharma franchise across India. Our portfolio spans 6 Artesunate formulations in Injection and Tablet forms, backed by consistent quality and monopoly-based distribution rights for our franchise partners.

What is Artesunate?

Artesunate is a water-soluble artemisinin derivative and the WHO-preferred treatment for severe malaria. It acts rapidly against the malaria parasite by generating free radicals that damage parasite proteins, clearing parasitaemia faster than older agents such as quinine. Its profile is documented on PubChem.

Therapeutic Applications

Artesunate injection is the first-line therapy for severe and cerebral Plasmodium falciparum malaria, while tablets are used in artemisinin-based combination therapy for uncomplicated malaria. It is prescribed mainly by hospital physicians, intensivists and paediatricians managing acute malaria in endemic and referral settings.

Why Artesunate is a High-Potential Molecule for Distributors

Because injectable artesunate is the global standard of care for severe malaria, it enjoys strong hospital and government-programme demand that is largely price-inelastic when a patient is critically ill. This makes it a dependable institutional line with healthy margins, complementing an artemether ACT range. Malaria-endemic districts offer distributors defensible, geography-based monopoly territories with recurring seasonal off-take.

Why Choose Cafoli Lifecare

Cafoli Lifecare offers district and state-wise monopoly rights, WHO-GMP certified and DCGI-approved manufacturing, attractive promotional inputs, and the backing of a network of 1000+ franchise partners. Our transparent supply and billing model helps you build a profitable, protected business in your territory.

References

1. PubChem — Artesunate
2. MedlinePlus — Malaria
3. PubMed — Artesunate literature